Anti-N-Glycolyl-GM3 monoclonal antibody - CIMAB

Drug Profile

Anti-N-Glycolyl-GM3 monoclonal antibody - CIMAB

Alternative Names: 14F7; 14F7 humanised mAb; 14F7h; Anti-N-Glycolyl-GM3 antibody 14F7; Humanised monoclonal antibody 14F7; Monoclonal antibody 14F7

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center of Molecular Immunology
  • Class Antineoplastics; Diagnostic agents; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Jun 2018 Clinical development planned for Cancer, including Solid tumours and B-cell lymphoproliferative syndrome (RPCEC00000266; RPCEC00000204)
  • 21 May 2018 Center of Molecular Immunology plans a phase I/II trial for B-cell lymphoproliferative syndrome (Second-line therapy or greater) in Cuba (RPCEC00000266)
  • 08 Sep 2016 The drug is still in preclinical development for Cancer in Cuba (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top